Emcure Pharmaceuticals Limited (NSE:EMCURE)

Emcure Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	9,244	6,813	4,982	5,320	6,622
Depreciation & Amortization	4,150	3,743	3,032	2,512	2,348
Other Amortization	-	97.98	92.56	89.04	100.28
Loss (Gain) From Sale of Assets	2.34	-382.35	-71.92	3.33	4.08
Loss (Gain) From Sale of Investments	-15.24	-58.04	-25.32	-1.21	-
Stock-Based Compensation	28.29	19.89	39.67	52.76	57.16
Other Operating Activities	1,327	2,526	2,419	2,415	1,469
Change in Accounts Receivable	-4,261	-1,434	-1,506	-3,398	-1,729
Change in Inventory	-3,838	-4,067	-267.61	663.85	-3,072
Change in Accounts Payable	2,765	1,702	1,543	-391.8	3,157
Change in Other Net Operating Assets	32.37	-443.61	736.2	203.54	-1,276
Operating Cash Flow	9,435	8,517	10,972	7,469	7,682
Operating Cash Flow Growth	10.78%	-22.38%	46.91%	-2.78%	9.05%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-3,606	-2,218	-2,758	-3,906	-3,782
Sale of Property, Plant & Equipment	42.6	306.01	315.37	12.75	31.21
Cash Acquisitions	-7,249	-	-3,451	-	-2,751
Sale (Purchase) of Intangibles	-1,871	-1,852	-313.6	-127.67	-187.87
Investment in Securities	734.94	2,592	-1,098	-708.36	-1,308
Other Investing Activities	17.72	231.44	179.46	152.4	109.49
Investing Cash Flow	-11,931	-940.01	-7,125	-4,577	-7,888

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	4,303	-	1,025	976.79	1,759
Long-Term Debt Issued	2,500	-	5,474	3,576	3,714
Total Debt Issued	6,803	-	6,500	4,553	5,473
Short-Term Debt Repaid	-	-5,225	-	-	-
Long-Term Debt Repaid	-1,918	-9,420	-5,310	-3,777	-4,814
Total Debt Repaid	-1,918	-14,645	-5,310	-3,777	-4,814
Net Debt Issued (Repaid)	4,884	-14,645	1,190	775.24	659.17
Issuance of Common Stock	66.46	7,792	76.6	-	-
Common Dividends Paid	-568.53	-	-542.55	-361.71	-542.55
Other Financing Activities	-947.89	-1,287	-2,366	-1,868	-1,635
Financing Cash Flow	3,434	-8,140	-1,642	-1,454	-1,519

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	181.55	-20.49	-20.02	-1.28	1.86
Miscellaneous Cash Flow Adjustments	-	-	-	-100	2,141
Net Cash Flow	1,121	-583.02	2,185	1,336	418.7

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	5,830	6,299	8,215	3,563	3,900
Free Cash Flow Growth	-7.45%	-23.32%	130.58%	-8.65%	-32.65%
Free Cash Flow Margin	6.33%	7.98%	12.34%	5.95%	6.66%
Free Cash Flow Per Share	30.76	33.68	45.42	19.70	21.57
Levered Free Cash Flow	3,113	2,777	3,670	1,625	2,297
Unlevered Free Cash Flow	4,011	3,591	4,940	2,781	3,216

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	947.89	1,287	2,082	1,786	1,553
Cash Income Tax Paid	3,681	2,469	2,237	2,005	3,112
Change in Working Capital	-5,301	-4,243	505.17	-2,922	-2,919

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 1, 2026

Data Sources Report a data error